NeurAxis Enhances Access to Innovative Treatment
NeurAxis, Inc. (NYSE American: NRXS), based in Carmel, Indiana, has recently achieved an important milestone in its mission to improve healthcare. The company announced its acquisition of a Veterans Affairs (VA) Federal Supply Schedule (FSS) contract designed to broaden access to its innovative treatment, IB-Stim, for individuals experiencing functional abdominal pain. This significant achievement, effective from December 1, 2025, not only positions NeurAxis strategically within the federal contracting space but also establishes a vital pathway to reaching nearly 7 million active patients receiving care through the VA healthcare system annually.
What is IB-Stim?
IB-Stim is a pioneering neuromodulation device that provides a drug-free treatment option for functional abdominal pain, particularly beneficial for patients aged 8 and above. The device functions by utilizing percutaneous electrical nerve field stimulation (PENFS), delivered through a non-invasive method that naturally influences pain signaling pathways between the gut and brain. For many patients, particularly those suffering from conditions like irritable bowel syndrome (IBS) and functional dyspepsia (FD), the lack of effective drug treatments has left a significant gap in care. With the addition of IB-Stim as a viable option, NeurAxis fills this pressing need, standing out as the only FDA-cleared therapy for treating these challenging conditions.
Implications for Veterans Using VA Healthcare
With the new VA contract, NeurAxis is poised to enhance the lives of countless veterans struggling with functional abdominal pain and associated conditions. As noted by CEO Brian Carrico, this contract marks a monumental step in their goal to extend the reach of IB-Stim to veteran patients suffering from these often debilitating symptoms. The inclusion in the VA system not only signifies a new commercial avenue for NeurAxis but also emphasizes the company’s commitment to supporting the health and well-being of those who have served.
Growth and Future Prospects
NeurAxis anticipates that this partnership with the VA, combined with increasing reimbursement policies and growing clinical acceptance, will create a robust momentum heading into 2026. The company is already creating dedicated sales efforts to tailor their approach to serve veteran patients better as utilization of the device expands. Furthermore, with a forthcoming Category I CPT code set to take effect in January 2026, there is an expectation of broader recognition of IB-Stim within clinical guidelines, potentially leading to sustained revenue growth and improved profit margins.
About NeurAxis, Inc.
NeurAxis is committed to revolutionizing how chronic and debilitating medical conditions are treated through advanced neuromodulation technologies. The company’s flagship product, the IB-Stim, is FDA-cleared, providing a platform for addressing functional abdominal pain related to conditions such as IBS and functional dyspepsia. Importantly, NeurAxis is actively conducting clinical trials to explore additional applications for their PENFS technology in both pediatric and adult populations where healthcare needs remain unmet. This dedication to innovation and evidence-based medicine positions NeurAxis as a leader in the evolving field of medical technology.
Frequently Asked Questions
What is the primary function of IB-Stim?
IB-Stim is designed to provide a drug-free treatment for functional abdominal pain, using electrical stimulation to help regulate pain signaling from the gut to the brain.
How does the Veterans Affairs contract benefit patients?
The VA contract enables greater access to IB-Stim for veterans suffering from pain and nausea associated with conditions like functional dyspepsia, ensuring they receive effective care.
What conditions can IB-Stim treat?
IB-Stim primarily targets functional abdominal pain linked to irritable bowel syndrome and functional dyspepsia, offering a much-needed therapeutic option.
When will NeurAxis implement the CPT code?
A Category I CPT code for IB-Stim will take effect on January 1, 2026, which can enhance reimbursement and clinical recognition for the treatment.
How is NeurAxis fostering growth?
NeurAxis plans to scale its efforts, focusing on increasing utilization of IB-Stim through dedicated sales strategies and ongoing clinical expansion models.
